Overview

Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients

Status:
Not yet recruiting

Trial end date:
2027-03-01

Target enrollment:

Participant gender:

Summary

This is a phase II randomized double-blind placebo-controlled trial that aims at evaluating the safety and tolerability of oral encapsulated fecal microbial transplantation therapy (MTT) in peanut allergic patients. In this research the investigators would like to learn more about ways to treat peanut allergies. The primary objective is to evaluate whether MTT with antibiotic pretreatment can increase the threshold of peanut reactivity during a double-blind placebo-controlled food challenge from <=100 mg peanut protein to 300 mg after 28 days of MTT /placebo therapy and 4 months post therapy initiation.

Phase:

Phase 2

Details

Lead Sponsor:

Rima Rachid

Collaborator:

University of Minnesota

Treatments:

Anti-Bacterial Agents
Antibiotics, Antitubercular